Crossmark

The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer

Crossref DOI link: https://doi.org/10.1007/s11864-019-0617-6

Published Online: 2019-02-18

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Perdrizet, Kirstin

Leighl, Natasha B.
License Information

Text and Data Mining valid from 2019-02-18
More Information

Article History

First Online: 18 February 2019

Compliance with Ethical Standards

:

: Kirstin Perdrizet declares that she has no conflict of interest.Natasha B. Leighl has received institutional research support from Array Biopharma; consulting fees from the Canadian Agency on Drugs and Technologies in Health; honoraria for independent CME lectures from AstraZeneca, Bristol-Myers Squibb, MSD, and Roche.

: This article does not contain any studies with human or animal subjects performed by any of the authors.